

or deep tissue cultures, empirical therapy prior to culture results may be indicated in patients with sepsis or cellulitis surrounding PODU. The objective of this retrospective case series is to develop an institutional protocol for empirical therapy of PODU when indicated based on local microbiology results.

**Methods.** Hospitalized adults with PODU from 1 August 2005 to 1 August 2015 at Palmetto Health hospitals in Columbia, SC were identified. PODU was defined based on clinical, radiographic, and microbiology criteria. Descriptive statistical methods (Fisher's exact) were used for preliminary analysis.

**Results.** Seventy-five cases with PODU were included with a mean age of 53 years and male predominance (48; 64%). The most common comorbidities were paraplegia (45, 60%), diabetes (23, 31%) and previous strokes (17, 23%). Forty-nine cases (65%) received antibiotics within a year of PODU. Prior infections or colonization with *P. aeruginosa* within the past year was present in 24/75 (32%) cases. Most cases had multiple sources of cultures: blood (61; 81%), bone/deep tissue (37; 49%), and/or superficial (73; 97%). Among a total of 99 clinical isolates, 56 (57%) were Gram-positive cocci (GPC) and 43 (43%) were Gram-negative bacilli (GNB). The most common organisms were *Enterobacteriaceae* (26; 26%), coagulase negative staphylococci (CONS) (20, 20%), *Staphylococcus aureus* (19, 19%), [12 (12%) methicillin-resistant *S. aureus*], and *P. aeruginosa* (9, 9%). Of the *Enterobacteriaceae*, 69% (18/26) were susceptible to ciprofloxacin and 88% (23/26) to ceftriaxone. All cases (9/9) of PODU due to *P. aeruginosa* had a prior infection/colonization with *P. aeruginosa* within 1 year as compared with 15/66 (23%) in those with PODU due to other organisms ( $P = 0.001$ ).

**Conclusion.** The microbiology of PODU is diverse (including GPC and GNB). Prior positive *P. aeruginosa* culture was a predictor of *P. aeruginosa* PODU. When empirical antimicrobial therapy is indicated, data support the use of intravenous vancomycin plus ceftriaxone in the absence of prior infection/colonization with *P. aeruginosa*, or intravenous vancomycin plus an anti-pseudomonal agent in the presence of prior *P. aeruginosa* within the past year.

**Disclosures.** All authors: No reported disclosures.

## 226. Clinical and Epidemiological Aspects Related to Infection of Orthopedic Prostheses in Argentinean Children. A 10-Year Period Study

Carlos Mauricio Vergara Lobo, MD<sup>1</sup>; Fausto M Ferolla, MD<sup>2</sup>; Elen Contreras, MD<sup>3</sup>; Carolina Carballo, MD<sup>4</sup>; Walter Yfran, MD<sup>5</sup>; Eugenia Pannunzio, MD<sup>6</sup>; Eliana Anteliz, MD<sup>7</sup>; Juan Reviriego, MD<sup>8</sup>; Maria Escalada, MD<sup>9</sup>; Gabriel Rositto, MD<sup>7</sup>; Carlos Legarreta, MD<sup>8</sup>; Claudia I. Cazes, MD<sup>9</sup>; María M. Contrini, MD<sup>2</sup> and Eduardo L. Lopez, MD<sup>10</sup>; <sup>1</sup>Infectología, Hospital de Niños "Ricardo Gutiérrez", Universidad de Buenos Aires, Buenos Aires, Argentina, <sup>2</sup>Infectious Disease Department, Hospital de Niños "Ricardo Gutiérrez", Buenos Aires, Argentina, <sup>3</sup>Infectious Diseases, Hospital de Niños "Ricardo Gutiérrez", Universidad de Buenos Aires, Buenos Aires, Argentina, <sup>4</sup>Infectious Diseases, Hospital Gutiérrez, Buenos Aires, Argentina, <sup>5</sup>Infectious Diseases, Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina, <sup>6</sup>Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina, <sup>7</sup>Traumatology and Orthopedics, Hospital de Niños "Dr. Ricardo Gutiérrez", Buenos Aires, Argentina, <sup>8</sup>Hospital de Niños, Buenos Aires, Argentina, <sup>9</sup>Hospital de Niños Dr. Ricardo Gutiérrez, Ciudad Autónoma de Buenos Aires, Argentina, <sup>10</sup>Department of Medicine, Hospital de Niños "Ricardo Gutiérrez", Buenos Aires, Argentina

**Session:** 45. Clinical: Bone and Joint Infection

**Thursday, October 5, 2017: 12:30 PM**


**Background.** Management of orthopedic prostheses infections (PI) in children is a main challenge, not only for the complexity of the disease but also for the scarce of evidence in this field.

**Objectives.** To describe the burden of PI and to analyze clinical and epidemiological aspects in pediatric patients.


**Methods.** Retrospective study in a tertiary pediatric hospital. Clinical charts of patients <18 years who underwent surgery for bone and/or joint implantation at "R. Gutiérrez" Children's Hospital in Buenos Aires from January 2007 to December 2016 were reviewed, and all PI cases were analyzed. PI was defined as early (E) when presentation was within 3 months of prosthesis implantation, delayed (D) when presenting between 3–24 months and late (L) if presenting beyond 2 years.

**Results.** 811 surgeries performed; 89 PI detected: E(n = 63); D(n = 9), L(n = 17); 58% male; median(m) age: 13 years (range[r] 4–20); m hospital stay 30 days (r 6–180). Annual incidence: 11% (CI95%: 8.9–13.1) (Figure 1). Underlying conditions: scoliosis (58.4%), malignancy (16.8%). Clinical features are detailed in Figure 2. Bacterial isolation in 63 (70.8%) cases, 51 (57.3%) with a single microorganism (Figure 3). Gram(+) bacteria were isolated in 58% of E PI, 86% of D PI and 49% of L PI. Gram(-) pathogens in 49% of E PI and in 38% of L PI. Three febrile PI (3,4%) had Gram(+) bacteremia, two of them L PI. No differences were seen in white blood cell count (WBC) and C-reactive protein(CRP) levels on admission in children with and without bacteremia, nor among the different types of PI; m WBC 9000/mm<sup>3</sup> (r 3200–25550), m CRP 37 mg/l (r 1–270). WBC on admission in MRSA PI was significantly higher,  $P < 0.01$ . Duration of EV treatment was different according to type of microorganism ( $P 0.03$ ), higher in PI by Gram(-). Forty-eight (53.9%) cases continued with trimethoprim-sulfamoxazole orally, without side effects requiring its discontinuation. Total treatment duration (m): 189 days (r 28–756). Eighty-two children (92.1%) underwent surgical toilette, 37 (45.1%) required more than one. Six (6.7%) presented relapse and eight (9%) reinfection.


**Conclusion.** PI in children is a considerable burden, with high morbidity. Incidence of bacteremia was low. Results of the study could help to delineate preventive strategies and improve decision making in PI in children.



**Fig. 2. Clinical manifestations**



**Fig. 3. Bacterial isolation**



**Disclosures.** All authors: No reported disclosures.

**227. Epidemiology and Clinical Features of Septic Arthritis in Children**  
Shannon Andrews, MD<sup>1</sup> and Bazak Sharon, MD<sup>2</sup>; <sup>1</sup>Medicine and Pediatrics, University of Minnesota, Minneapolis, Minnesota, <sup>2</sup>Pediatric Infectious Diseases, University of Minnesota, Minneapolis, Minnec

**Session:** 45. Clinical: Bone and Joint Infection  
**Thursday, October 5, 2017: 12:30 PM**


**Background.** Children with acute arthritis are commonly admitted to the hospital in part due to concern for septic arthritis (SA) and its complications. Many noninfectious, non-urgent conditions are more common than SA and present similarly. The epidemiology and clinical presentation of SA influences management of patients with acute arthritis.

**Methods.** Utilizing the electronic medical record, we reviewed the charts of children (1–18 years old) with joint complaints who presented to the hospitals and clinics of one large academic health organization in the Upper Midwest from January 2011 to July 2016. Query criteria included the presenting symptom (“arthritis”, “joint swelling”, or “joint pain”), diagnosis (“arthritis”, “septic arthritis”, or “Lyme arthritis”), and/or positive synovial fluid culture. SA was confirmed when synovial bacterial culture or PCR were positive. SA was suspected in cases with a positive blood culture or when the patient was treated empirically with 4 weeks of antibiotic with no alternate diagnosis. All other children were excluded from the study cohort.

**Results.** Of the 705 children whose charts were reviewed, 609 were excluded with a noninfectious diagnosis and 72 with Lyme arthritis (Figure 1). We identified 24 children with SA. Six children diagnosed with SA were immunosuppressed. Among healthy children with SA, seven were diagnosed with contiguous musculoskeletal (MSK) infection and 11 were diagnosed with acute, isolated, monoarticular arthritis. SA was more common in boys. The most common pathogen isolated was *S aureus* (13). The knee (7) and hip (6) accounted for the majority of joints involved in healthy children.

**Conclusion.** SA is a rare cause of acute arthritis in children. In healthy children, SA may present with contiguous MSK infection or in an isolated joint. SA is more likely in boys and in the knee or hip joint. *S. aureus* is the most common cause of SA. Clear understanding of the epidemiology and clinical history of SA should shape clinical decision making in children with acute arthritis.

Figure 1. MSK – musculoskeletal, SA – septic arthritis, OM – osteomyelitis, DVT – deep venous thrombosis, Cx – culture negative.



**Disclosures.** All authors: No reported disclosures.

**228. The Use of Rifampin Therapy to Treat Diabetic Patients with Osteomyelitis of the Foot in the Veterans Health Administration: Patient Characteristics and Clinical Outcomes**

Brigid Wilson, PhD<sup>1,2</sup>; Elie Saade, MD, MPH<sup>3</sup>; Gheorghe Doros, PhD<sup>4,5</sup>; John Hermos, MD<sup>4,5</sup>; Mary Besesen, MD<sup>6,7</sup> and Robert A. Bonomo, MD<sup>8,9</sup>; <sup>1</sup>Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, <sup>2</sup>Geriatric Research, Education, and Clinical Center, Cleveland VA Medical Center, Cleveland, Ohio, <sup>3</sup>Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, <sup>4</sup>Boston University, Boston, Massachusetts, <sup>5</sup>Massachusetts Veterans Epidemiology Research and Information Center, Boston, Massachusetts, <sup>6</sup>Medicine, University of Colorado Denver, Aurora, Colorado, <sup>7</sup>VA Eastern Colorado Healthcare System, Denver, Colorado, <sup>8</sup>Medicine, Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, <sup>9</sup>Case Western Reserve University, Cleveland, Ohio

**Session:** 45. Clinical: Bone and Joint Infection  
**Thursday, October 5, 2017: 12:30 PM**

**Background.** Nearly 25% of Veterans Health Administration (VHA) patients are diagnosed with diabetes mellitus (DM). Among DM patients, the lifetime incidence of foot ulcers is 15%. Infection is a common complication of foot ulcers and 20–60% of infections result in diabetic foot osteomyelitis (DFO). Current treatment guidelines do not endorse any specific antibiotic agent for DFO, but small clinical trials suggest the addition of rifampin to antimicrobial regimens results in improved cure rates for osteomyelitis.


**Methods.** Using VHA databases, we identified index DFO cases from 2009 to 2013 and extracted patient and infection characteristics including demographics, comorbidities, chronic medications, antibiotic regimens, and microbiology data when present. We analyzed the subset of patients alive, without high-level amputation, and treated with antibiotics at 90 days after diagnosis. We summarized patient characteristics and compared a composite endpoint of amputation or death within 2 years of DFO diagnosis among those treated with rifampin to those not treated with rifampin.

**Results.** In total, 10,736 DFO cases met our criteria (Figure). Of these, 151 were considered treated with rifampin, based on 14 or more days of rifampin initiated within 90 days of diagnosis; 10,551 were unexposed to rifampin; and 34 were excluded for late or short treatment with rifampin. We observed significant differences between patients treated with and without rifampin (Table) and 44% of rifampin-treated patients were seen in 14 facilities.

Amputation or death at 2 years was observed in 44 (29%) of patients treated with rifampin and 4,007 (38%) of patients not treated with rifampin ( $P = 0.03$ ).

**Conclusion.** Rifampin was rarely used in the treatment of DFO in the VHA and a few facilities accounted for a large proportion of rifampin-treated cases. We observed higher rates of amputation-free survival in patients treated with rifampin, but in the presence of notable confounders including age, comorbidities, and organism.

|                                 | Not treated with rifampin<br>N = 10,551 | Treated with rifampin<br>N = 151 | P-value |
|---------------------------------|---|----------------------------------|---------|
| Age (mean)                      | 65                                      | 62                               | <0.01   |
| Charlson comorbidity (mean)     | 4.0                                     | 3.5                              | <0.01   |
| Warfarin (prior 6 months) (%)   | 9.7                                     | 6.6                              | 0.25    |
| <i>S. aureus</i> identified (%) | 33.9                                    | 45.7                             | <0.01   |
| Complex VA Medical Center (%)   | 39.4                                    | 45.0                             | 0.19    |



**Disclosures.** E. Saade, Steris: Grant Investigator, Grant recipient. Janssen: Grant Investigator, Research grant. Sequiris: Grant Investigator, Research grant. Pfizer: Grant Investigator, Research grant. R. A. Bonomo, Entasis: Grant Investigator, Research grant. Allegra: Grant Investigator, Research grant. Wockhardt: Grant Investigator, Research grant. Merck: Grant Investigator, Research grant. Roche: Grant Investigator, Research grant. GSK: Grant Investigator, Research grant. Allergan: Grant Investigator, Research grant. Shionogi: Grant Investigator, Research grant

**229. Recent Respiratory Tract Infection and Additional Surgeries Increase Risk for Surgical Site Infection in Total Joint Arthroplasty: A Retrospective Analysis of 2255 Patients**

Bhagyashri Navalkele, MD<sup>1</sup>; Amar Krishna, MD<sup>2</sup>; George McKelvey, PhD<sup>3</sup>; Samuel Perov, MD<sup>3</sup>; Kunal Sood, MD<sup>3</sup>; Youssef Dakallah, MD<sup>3</sup> and Teena Chopra, MD MPH<sup>4</sup>; <sup>1</sup>Division of Infectious Diseases, Department of Internal Medicine, Wayne State University, Detroit, Michigan, <sup>2</sup>Infectious Disease, Detroit Medical Center/Wayne State University, Detroit, Michigan, <sup>3</sup>Detroit Medical Center, Detroit, Michigan, <sup>4</sup>Infectious Diseases, Detroit Medical Center/Wayne State University, Detroit, Michigan

**Session:** 45. Clinical: Bone and Joint Infection  
**Thursday, October 5, 2017: 12:30 PM**